The Fusion Protein of IFN-α and Apolipoprotein A-I Crosses the Blood–Brain Barrier by a Saturable Transport Mechanism

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Immunology

• Publication date

  2012-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1101598PMID 22422884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon-α-2a (40kD)

  2012cited by this paper
• Anchoring interferon alpha to apolipoprotein A‐I reduces hematological toxicity while enhancing immunostimulatory properties

  2011cited by this paper
• Administration of Interferon-Alpha in Mice Provokes Peripheral and Central Modulation of Immune Cells, Accompanied by Behavioral Effects

  2009cited by this paper
• Specific Loss of Brain ABCA1 Increases Brain Cholesterol Uptake and Influences Neuronal Structure and Function

  2009cited by this paper
• Systemic interferon-α regulates interferon-stimulated genes in the central nervous system

  2008cited by this paper
• From inflammation to sickness and depression: when the immune system subjugates the brain

  2008cited by this paper
• Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system.

  2008cited by this paper
• Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.

  2007cited by this paper
• An Interferon α2 Mutant Optimized by Phage Display for IFNAR1 Binding Confers Specifically Enhanced Antitumor Activities*

  2007cited by this paper
• Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier.

  2007cited by this paper
• The tail suspension test: A new method for screening antidepressants in mice

  2004cited by this paper
• Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model

  2004cited by this paper
• Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.

  2003cited by this paper
• Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

  2002cited by this paper
• Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

  2002cited by this paper
• Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

  2001cited by this paper
• Prolonging the half-life of human interferon-α2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-α2

  2001cited by this paper
• Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.

  2001cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

  2000cited by this paper
• Brain lipoprotein metabolism and its relation to neurodegenerative disease.

  1999cited by this paper
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999cited by this paper
• Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.

  1999cited by this paper
• The role of interferon-alpha in the treatment of myeloproliferative disorders.

  1999cited by this paper
• Endocrine and metabolic effects of interferon-alpha in humans.

  1996cited by this paper
• Cytokines and the nervous system II: Actions and mechanisms of action.

  1995cited by this paper
• Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat.

  1988cited by this paper
• Pharmacokinetics and biodisposition of recombinant human interferon-alpha 2C in rat and marmoset.

  1988cited by this paper
• Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.

  1988cited by this paper
• Psychiatric complications of long-term interferon alfa therapy.

  1987cited by this paper
• Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration

  1985cited by this paper
• Virus interference. I. The interferon

  1957cited by this paper

• SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma

  2026cites this paper
• Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing

  2025influential citation
• Engineering interferons for cancer immunotherapy.

  2024cites this paper
• Overcoming the limitations of cytokines to improve cancer therapy.

  2022cites this paper
• Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

  2022cites this paper
• Cancer immunotherapy: diverse approaches and obstacles.

  2022cites this paper
• The SR-B1 Receptor as a Potential Target for Treating Glioblastoma

  2019cites this paper
• Successful treatment of central nervous system involved Erdheim–Chester disease by intermediate-dose cytarabine as first-line therapy

  2019cites this paper
• High yield expression, characterization, and biological activity of IFNα2-Tα1 fusion protein

  2019cites this paper
• Cytokines in clinical cancer immunotherapy

  2018cites this paper
• Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.

  2017cites this paper
• BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.

  2015cites this paper
• Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.

  2015cites this paper
• Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.

  2015cites this paper
• Crucial role of the protein corona for the specific targeting of nanoparticles.

  2015cites this paper
• Targeting low-density lipoprotein receptors with protein-only nanoparticles

  2015influential citation
• Regulation and transport of apolipoprotein A-I into the central nervous system and therapeutic potential in Alzheimer's disease

  2014cites this paper
• High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease.

  2014influential citation
• Fusion Proteins with a Targeting Function

  2013cites this paper
• Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives

  2013cites this paper
• N-acetyl-cysteine prevents toxic oxidative effects induced by IFN-α in human neurons.

  2013cites this paper